Investor/Media Center

Press Releases


 
Aug 18, 2014 Bio-Path Holdings Reports Second Quarter 2014 Operational and Financial Results
Jun 30, 2014 Bio-Path Holdings Added to Russell Global, Russell 3000 and Russell Microcap Indexes
Jun 19, 2014 Enrollment Continues Into Bio-Path Holdings Phase I Clinical Trial
May 19, 2014 Bio-Path Holdings Reports First Quarter 2014 Operational and Financial Results
Apr 1, 2014 Bio-Path Holdings Reports Fiscal Year 2013 Operational and Financial Results
Mar 26, 2014 Bio-Path Holdings, Inc. Appoints Ulrich M. Mueller Chief Operating Officer
Mar 5, 2014 Bio-Path Holdings Announces Uplisting to the NASDAQ Capital Market
Jan 16, 2014 Bio-Path Holdings, Inc. to Raise $10 Million in Registered Direct Offering
Jan 7, 2014 Bio-Path Holdings to Present at the Biotech Showcase 2014 Conference in San Francisco, CA on Wednesday, January 15, 2014 at 8:00 a.m. Pacific Time
Dec 9, 2013 Preliminary Results from Bio-Path Holdings' Phase I Clinical Trial Presented at the Annual Meeting of the American Society of Hematology (ASH) in New Orleans
Nov 15, 2013 Bio-Path Holdings Reports Third Quarter 2013 Operational and Financial Results
Nov 7, 2013 Data from Bio-Path Holdings Phase I Clinical Trial in Hematological Cancers to be Presented at American Society of Hematology Annual Meeting: Data Suggests Potential for AML and MDS Disease Inhibition with Liposomal Grb-2-
Oct 1, 2013 Bio-Path Holdings to Present at the 12th Annual BIO Investor Forum
Sep 19, 2013 Bio-Path Holdings, Inc. Retains Investment Banking Firm Maxim Group LLC
Aug 15, 2013 Bio-Path Holdings Reports Second Quarter 2013 Operational and Financial Results
Aug 9, 2013 Bio-Path Holdings' Liposomal Delivery Technology Achieves Major Milestone in development of Antisense Therapeutics
Jul 22, 2013 Bio-Path Holdings Initiates Development of Liposomal Grb-2 for Triple Negative and Inflammatory Breast Cancers
Jun 6, 2013 Bio-Path Holdings Successfully Completes Fifty Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia
May 16, 2013 Bio-Path Holdings Reports First Quarter 2013 Operational and Financial Results
Apr 2, 2013 Bio-Path Holdings Reports Fiscal Year 2012 Operational and Financial Results
Mar 7, 2013 Bio-Path Holdings Begins Enrollment in Fifth Cohort of Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemias
Jan 3, 2013 Bio-Path Holdings to Present at Biotech Showcase 2013 Conference in San Francisco, California on Tuesday, January 8, 2013 at 11:00 am Pacific Time
Dec 6, 2012 Bio-Path Holdings to Expand Development of Liposomal Grb-2 into two additional indications: Triple Negative and Inflammatory Breast Cancers
Nov 16, 2012 Bio-Path Holdings Reports Third Quarter 2012 Operational and Financial Results
Nov 14, 2012 Bio-Path Holdings Successfully Completes Fourth Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia
Oct 4, 2012 Bio-Path Holdings Adds New Board Member
Oct 3, 2012 Bio-Path Holdings to Present at the 11th Annual Bio Investor Forum Conference in San Francisco on Wednesday Oct 10, 2012 at 11:30 am Pacific Time (2:30 pm Eastern Time)

Webcast link here.

Sep 4, 2012 Bio-Path Holdings to Present at the Rodman & Renshaw Annual Global Investment Conference
Aug 24, 2012 Bio-Path Holdings to Present at the 2012 Southern California Investor Conference
Webcast Link Here
Aug 16, 2012 Bio-Path Holdings Reports Second Quarter 2012 Operational and Financial Results
Jul 25, 2012 Bio-Path Holdings Begins Enrollment in Fourth Cohort of Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemias
Jun 4, 2012 Bio-Path Holdings Shares Commence Trading On OTCQX, The Top Tier Of The OTC Market
May 29, 2012 Bio-Path Holdings Successfully Completes Third Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia
May 17, 2012 Bio-Path Holdings Reports First Quarter 2012 Operational and Financial Results - Quarter Highlighted by Progress with Lead Product Candidate, Liposomal Grb-2
Apr 3, 2012 Bio-Path Holdings Reports Fiscal Year 2011 Operational and Financial Results
Mar 29, 2012 Bio-Path Holdings Engages PondelWilkinson for Retailer Investor Relations Program
Feb 7, 2012 Bio-Path Holdings Successfully Completes Second Cohort in
Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia
Jan 4, 2012 Bio-Path Holdings to Present at Biotech Showcase 2012 Conference
Dec 13, 2011 Bio-Path Holdings' Initial Phase I Data in Leukemia Clinical Trial Demonstrates that Its Neutral Lipid Delivery Technology Antisense Drug BP-101-100-1.01 (Liposomal Grb-2) Is Well Tolerated with Activity Seen at Low-Starting Dose
Nov 15, 2011 Press Release Form 8-K - 3rd Quarter Financial Results
Oct 24, 2011 Proxy Statement fothereer 2011
Oct 19, 2011 Bio-Path Holdings to Present at the 10th Annual BIO Investors Forum Conference in San Francisco on Wednesday, October 26, 2011. Link to Conference at 3:00pm Pacific Time
Oct 4, 2011 Initial Data from Bio-Path Holdings' Phase I Clinical Trial Accepted for Presentation at American Society ofHematology Annual Meeting
Sep 6, 2011 Bio-Path Holdings to Present at the Rodman & RenshawAnnual Global Investment Conference 
Link to Conference on September 13, 2011 at 4:55 pm Eastern Time
Aug 11, 2011 First Cohort Successfully Completed in Bio-Path Holding’s Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia
Jul 27, 2011 Bio-Path recently featured in Genomeweb/Gene Silencing News
May 17, 2011 Bio-Path Holdings Reports First Quarter 2011 Financial Results
Apr 28, 2011 Bio-Path Holdings Appoints Dr. Ana M. Tari Director, Preclinical Operations and Research
Apl 4, 2011 Zack's Small-Cap Research Release
Mar 31, 2011 Bio-Path Holdings Reports Fiscal Year 2010 Operation and Financial Results
Feb 23, 2011 CEOCFO Interviews Peter H. Nielsen, CEO
Feb 23, 2011 Zack's Small-Cap Research Release
Nov 15, 2010 Bio-Path Holdings Reports Third Quarter 2010 Financial Results
Nov 3, 2010 Bio-Path Holdings Awarded Grant From The U.S. Government's Qualifying Therapeutic Discovery Project Program
Aug 17, 2010 Bio-Path Holdings Reports Fiscal 2010 Second Quarter Financial Results
Company Also Completes Initial Sale of Registered Shares Under Financing With Lincoln Park Capital 
Jul 29, 2010 Bio-Path Holdings announces Dosing of First Patient in a Phase I Clinical Trial of its Liposomal Grb-2 Cancer Drug Candidate
Jun 4, 2010 Bio-Path Holdings Signs Equity Financing Deal
Equity Purchase Agreement With Institutional Investor Lincoln Park Capital to Provide Up to $7 Million In New Capital

Mar 12, 2010 FDA Allows IND For Bio-Path Holdings' Liposomal Grb-2
Company to Commence Phase I Clinical Trial Of Its Cancer Drug To Treat CML, AML, ALL, & MDS
 
Dec 14, 2009 Bio-Path Holdings, Inc. Completes Private Placement Capital Raise and Provides Update to IND Status  
Nov 2, 2009 Bio-Path Holdings, Inc. Operations Update
Sep 22, 2009 Bio-Path Holdings, Inc. Announces Plans To Develop
Liposome Tumor Targeting Technology Licensed from The
University of Texas M. D. Anderson Cancer Center
Jun 23, 2009 Bio-Path Holdings, Inc. Provides Operations Update and Overview Of New Targeting Technology
Jun 6, 2009   Proxy Statement and Proxy
Apr 14, 2009 Bio-Path Holdings, Inc. Announces Clinical Support Agreement With ACORN And Names Bradley G. Somer, M.D., As Medical Officer For Phase I Clinical Trial  
Dec 10, 2008 Letter To Shareholders
Dec 3, 2008 Bio-Path Holdings, Inc. Retains Alliance Advisors, LLC to Implement Investor Relations Program
Nov 17, 2008 Bio-Path Holdings, Inc. Announces the Signing of a Drug Manufacturing Agreement with Althea Technologies, Inc.
Jun 23, 2008 Bio-Path Holdings Announces Dr. Hans A. de Hann Has Joined The Company As Medical Director
Mar 3, 2008 Bio-Path Becomes a Publicly Traded Company